TPTX News and Press, Turning Point Therapeutics Inc. From 07/22/19

SAN DIEGO, July 22, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report second quarter financial results following the close of U.S. financial markets on Aug. 6 and host a ...

SAN DIEGO, June 20, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients wit...

SAN DIEGO, June 04, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session a...

The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with this Read more ...

Gainers:  Stellar Biotechnologies (NASDAQ: SBOT ) +55% . Genocea Biosciences (NASDAQ: GNCA ) +52% . Mmtec (NASDAQ: MTC ) +27% . Capital Senior Living Corporation (NYSE: CSU ) +18% . Genesco (NYSE: GCO ) +13% . Williams-Sonoma (NYSE: WSM ) +13% . GTx (NASDAQ: GTXI ) +12% . Charl...

In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Duration of Response across all Dose Levels Not Yet Reached Since Prior Update, Overall Response Rate by Blinded...

SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug (...

SAN DIEGO, May 14, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in...

SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Fo...